{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:47:15Z","timestamp":1790801235520,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH RO1","award":["1R01AI145045IH"],"award-info":[{"award-number":["1R01AI145045IH"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Human immunodeficiency virus (HIV) infections and HIV-induced acquired immunodeficiency syndrome (AIDS) continue to represent a global health burden. There is currently no effective vaccine, nor any cure, for HIV infections; existing antiretroviral therapy can suppress viral replication, but only as long as antiviral drugs are taken. HIV infects cells of the host immune system, and it can establish a long-lived viral reservoir, which can be targeted and edited through gene therapy. Gene editing platforms based on the clustered regularly interspaced palindromic repeat-Cas system (CRISPR-Cas) have been recognized as promising tools in the development of gene therapies for HIV infections. In this review, we evaluate the current landscape of CRISPR-Cas-based therapies against HIV, with an emphasis on the infection biology of the virus as well as the activity of host restriction factors. We discuss the potential of a combined CRISPR-Cas approach that targets host and viral genes to activate antiviral host factors and inhibit viral replication simultaneously. Lastly, we focus on the challenges and potential solutions of CRISPR-Cas gene editing approaches in achieving an HIV cure.<\/jats:p>","DOI":"10.3390\/ijms24021563","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:05:52Z","timestamp":1673575552000},"page":"1563","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A CRISPR-Cas Cure for HIV\/AIDS"],"prefix":"10.3390","volume":"24","author":[{"given":"Mouraya","family":"Hussein","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4260-0509","authenticated-orcid":false,"given":"Mariano A.","family":"Molina","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Berkhout","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-8552","authenticated-orcid":false,"given":"Elena","family":"Herrera-Carrillo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2021, November 16). UNAIDS Data 2019. Available online: https:\/\/www.unaids.org\/en\/resources\/documents\/2019\/2019-UNAIDS-data."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/14787210.2014.910112","article-title":"A cure for HIV: Is it in sight?","volume":"12","author":"Pace","year":"2014","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","article-title":"Antiretroviral therapy: Current drugs","volume":"28","author":"Pau","year":"2014","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.idc.2019.05.003","article-title":"Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?","volume":"33","author":"Kelly","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E424","DOI":"10.1016\/S2352-3018(17)30112-1","article-title":"Second-line antiretroviral therapy: So much to be done","volume":"4","author":"Assefa","year":"2017","journal-title":"Lancet Hiv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","article-title":"Why and where an HIV cure is needed and how it might be achieved","volume":"576","author":"McCune","year":"2019","journal-title":"Nature"},{"key":"ref_7","first-page":"91","article-title":"Advances toward a cure for HIV: Getting beyond n = 2","volume":"27","author":"Li","year":"2020","journal-title":"Top Antivir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","article-title":"Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance","volume":"48","author":"Bandera","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1924","DOI":"10.1002\/rmv.1924","article-title":"Mechanisms of HIV persistence in HIV reservoirs","volume":"27","author":"Mzingwane","year":"2017","journal-title":"Rev. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/aid.2018.0118","article-title":"Barriers for HIV Cure: The Latent Reservoir","volume":"34","year":"2018","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14787210.2017.1353911","article-title":"Fight fire with fire: Gene therapy strategies to cure HIV","volume":"15","author":"Huyghe","year":"2017","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3389\/fmicb.2018.03107","article-title":"CRISPR\/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus","volume":"9","author":"Panfil","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.molcel.2014.03.011","article-title":"CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity","volume":"54","author":"Barrangou","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1126\/science.1159689","article-title":"Small CRISPR RNAs guide antiviral defense in prokaryotes","volume":"321","author":"Brouns","year":"2008","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 Structures and Mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1093\/nar\/gkaa272","article-title":"Characterization of Cas12a nucleases reveals diverse PAM profiles between closely-related orthologs","volume":"48","author":"Jacobsen","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1038\/s41598-020-68459-4","article-title":"Structure-based design of gRNA for Cas13","volume":"10","author":"Bandaru","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","article-title":"DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing","volume":"37","author":"Xue","year":"2021","journal-title":"Trends Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","article-title":"CRISPR-Cas12a: Functional overview and applications","volume":"43","author":"Paul","year":"2020","journal-title":"Biomed. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2022.02.010","article-title":"A combinatorial CRISPR-Cas12a attack on HIV DNA","volume":"25","author":"Fan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18457","DOI":"10.1038\/s41598-020-75295-z","article-title":"Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos","volume":"10","author":"Schmidt","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.omtn.2020.05.030","article-title":"CRISPR-Cas13a Inhibits HIV-1 Infection","volume":"21","author":"Yin","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jmb.2018.06.037","article-title":"A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology","volume":"431","author":"Xu","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41467-017-02265-x","article-title":"Engineering cell signaling using tunable CRISPR-Cpf1-based transcription factors","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1038\/ncomms7413","article-title":"Use of the CRISPR\/Cas9 system as an intracellular defense against HIV-1 infection in human cells","volume":"6","author":"Liao","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"3","author":"Ebina","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"22555","DOI":"10.1038\/srep22555","article-title":"Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR\/Cas9 Gene Editing","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2017.11.006","article-title":"Delineation of the exact transcription termination signal for type 3 Polymerase III","volume":"10","author":"Gao","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1080\/15476286.2018.1551703","article-title":"Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA","volume":"15","author":"Gao","year":"2018","journal-title":"RNA Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/21541264.2017.1322170","article-title":"Mutation of nucleotides around the +1 position of type 3 polymerase III promoters: The effect on transcriptional activity and start site usage","volume":"8","author":"Gao","year":"2017","journal-title":"Transcription"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2018.05.001","article-title":"RNA Polymerase II Activity of Type 3 Pol III Promoters","volume":"12","author":"Gao","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtn.2018.10.016","article-title":"A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System","volume":"14","author":"Gao","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Darcis, G., Binda, C.S., Klaver, B., Herrera-Carrillo, E., Berkhout, B., and Das, A.T. (2019). The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape. Viruses, 11.","DOI":"10.3390\/v11030255"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/gt.2015.11","article-title":"The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy","volume":"22","author":"Berkhout","year":"2015","journal-title":"Gene Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7784","DOI":"10.1038\/s41598-018-26190-1","article-title":"CRISPR\/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures","volume":"8","author":"Ophinni","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.celrep.2016.11.057","article-title":"A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures","volume":"17","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1093\/nar\/gkaa226","article-title":"Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA","volume":"48","author":"Gao","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ophinni, Y., Miki, S., Hayashi, Y., and Kameoka, M. (2020). Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape. Viruses, 12.","DOI":"10.3390\/v12111223"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103678","DOI":"10.1016\/j.ebiom.2021.103678","article-title":"CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination","volume":"73","author":"Herskovitz","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/mt.2016.24","article-title":"CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape","volume":"24","author":"Wang","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/QAD.0000000000001079","article-title":"Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS","volume":"30","author":"Yin","year":"2016","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","article-title":"In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models","volume":"25","author":"Yin","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nguyen, H., Wilson, H., Jayakumar, S., Kulkarni, V., and Kulkarni, S. (2021). Efficient Inhibition of HIV Using CRISPR\/Cas13d Nuclease System. Viruses, 13.","DOI":"10.1101\/2021.07.21.453273"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/aid.2017.0234","article-title":"In Vitro Transduction and Target-Mutagenesis Efficiency of HIV-1 pol Gene Targeting ZFN and CRISPR\/Cas9 Delivered by Various Plasmids and\/or Vectors: Toward an HIV Cure","volume":"34","author":"Okee","year":"2018","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31527","DOI":"10.1038\/srep31527","article-title":"Negative Feedback Regulation of HIV-1 by Gene Editing Strategy","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1073\/pnas.1405186111","article-title":"RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection","volume":"111","author":"Hu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E7249","DOI":"10.1073\/pnas.1516305112","article-title":"Specific induction of endogenous viral restriction factors using CRISPR\/Cas-derived transcriptional activators","volume":"112","author":"Bogerd","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1038\/s41598-019-40003-z","article-title":"CRISPR-mediated activation of endogenous BST-2\/tetherin expression inhibits wild-type HIV-1 production","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17113","DOI":"10.1038\/s41598-017-17180-w","article-title":"CRISPR\/Cas9 delivery with one single adenoviral vector devoid of all viral genes","volume":"7","author":"Schiwon","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem\/Progenitor Cells Confers HIV-1 Resistance In Vivo","volume":"25","author":"Xu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13578-017-0174-2","article-title":"Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection","volume":"7","author":"Liu","year":"2017","journal-title":"Cell Biosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/431682","article-title":"HIV superinfection","volume":"192","author":"Smith","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_64","first-page":"96","article-title":"Clinical Relevance of HIV-1 Superinfection","volume":"79","author":"Hoogmoed","year":"2011","journal-title":"HIV-Host Interact."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-4690-2-52","article-title":"Retroviral superinfection resistance","volume":"2","author":"Nethe","year":"2005","journal-title":"Retrovirology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0042-6822(03)00126-0","article-title":"Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1","volume":"311","author":"Tanaka","year":"2003","journal-title":"Virology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1570162043485086","article-title":"Role of CD4 receptor down-regulation during HIV-1 infection","volume":"2","author":"Levesque","year":"2004","journal-title":"Curr. HIV Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1073\/pnas.90.12.5549","article-title":"CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals","volume":"90","author":"Mariani","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1084\/jem.177.6.1561","article-title":"Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection","volume":"177","author":"Benson","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0092-8674(94)90360-3","article-title":"Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain","volume":"76","author":"Aiken","year":"1994","journal-title":"Cell"},{"key":"ref_71","first-page":"85","article-title":"Tat and Rev: Positive modulators of human immunodeficiency virus gene expression","volume":"1","author":"Rosen","year":"1991","journal-title":"Gene Expr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/molbev\/mst094","article-title":"The effect of gene overlapping on the rate of RNA virus evolution","volume":"30","author":"Holmes","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.cell.2016.11.031","article-title":"Functional Segregation of Overlapping Genes in HIV","volume":"167","author":"Fernandes","year":"2016","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1089\/aid.2015.0150","article-title":"Positive Selection Analysis of Overlapping Reading Frames Is Invalid","volume":"31","author":"Monit","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0014-5793(01)02364-X","article-title":"Functional role of the HIV-1 Rev exon 1 encoded region in complex formation andtrans-dominant inhibition","volume":"495","author":"Gjerdrum","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"German Advisory Committee Blood (2016). Human Immunodeficiency Virus (HIV). Transfus. Med. Hemother., 43, 203\u2013222.","DOI":"10.1159\/000445852"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1006\/viro.1994.1683","article-title":"Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1","volume":"205","author":"Little","year":"1994","journal-title":"Virology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature15399","article-title":"HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation","volume":"526","author":"Rosa","year":"2015","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature15400","article-title":"SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef","volume":"526","author":"Usami","year":"2015","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-1097(03)00067-3","article-title":"HIV Tat, its TARgets and the control of viral gene expression","volume":"220","author":"Brigati","year":"2003","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.016303-0","article-title":"Functions of Tat: The versatile protein of human immunodeficiency virus type 1","volume":"91","author":"Romani","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"27569","DOI":"10.18632\/oncotarget.15174","article-title":"Tat is a multifunctional viral protein that modulates cellular gene expression and functions","volume":"8","author":"Clark","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rolland, M., Nickle, D.C., and Mullins, J.I. (2007). HIV-1 group M conserved elements vaccine. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030157"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1348-0421.12395","article-title":"Anti-HIV-1 potency of the CRISPR\/Cas9 system insufficient to fully inhibit viral replication","volume":"60","author":"Ueda","year":"2016","journal-title":"Microbiol. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nm0804-769","article-title":"Urgently needed: A filter for the HIV-1 vaccine pipeline","volume":"10","author":"Moore","year":"2004","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kluge, S.F., Sauter, D., and Kirchhoff, F. (2015). SnapShot: Antiviral restriction factors. Cell, 163.","DOI":"10.1016\/j.cell.2015.10.019"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1099\/jgv.0.001026","article-title":"Novel host restriction factors implicated in HIV-1 replication","volume":"99","author":"Ghimire","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.chom.2010.06.004","article-title":"Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses","volume":"8","author":"Kirchhoff","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chom.2008.04.008","article-title":"HIV-1 accessory proteins--ensuring viral survival in a hostile environment","volume":"3","author":"Malim","year":"2008","journal-title":"Cell Host Microbe"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.coviro.2013.08.004","article-title":"HIV accessory proteins versus host restriction factors","volume":"3","author":"Strebel","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/nar\/gkh554","article-title":"APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase","volume":"32","author":"Suspene","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nsmb758","article-title":"Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome","volume":"11","author":"Yu","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1074\/jbc.M313093200","article-title":"Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway","volume":"279","author":"Mehle","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pro.3729","article-title":"Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions","volume":"29","author":"Azimi","year":"2020","journal-title":"Protein Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbrc.2021.08.031","article-title":"STUB1\/CHIP promotes ubiquitination and degradation of HIV-1 Vif to restore the cellular level of APOBEC3G protein","volume":"574","author":"Ali","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ni.2236","article-title":"SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates","volume":"13","author":"Lahouassa","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm.3626","article-title":"The ribonuclease activity of SAMHD1 is required for HIV-1 restriction","volume":"20","author":"Ryoo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"109105","DOI":"10.1016\/j.celrep.2021.109105","article-title":"Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins","volume":"35","author":"Hiatt","year":"2021","journal-title":"Cell Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2019.03.018","article-title":"The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxB","volume":"531","author":"Buffone","year":"2019","journal-title":"Virology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Sch\u00fcssler, M., Rauch, P., Schott, K., Oo, A., Fuchs, N.V., Kim, B., and K\u00f6nig, R. (2022). CRISPR\/Cas9 knock-in strategy to evaluate phospho-regulation of SAMHD1. bioRxiv.","DOI":"10.1101\/2022.01.04.475018"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1570162052772988","article-title":"The role of Vpr in HIV-1 pathogenesis","volume":"3","author":"Andersen","year":"2005","journal-title":"Curr. HIV Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cell.2013.12.011","article-title":"Premature activation of the SLX4 complex by Vpr promotes G2\/M arrest and escape from innate immune sensing","volume":"156","author":"Laguette","year":"2014","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12977-014-0117-5","article-title":"How SLX4 cuts through the mystery of HIV-1 Vpr-mediated cell cycle arrest","volume":"11","author":"Blondot","year":"2014","journal-title":"Retrovirology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/JVI.02307-14","article-title":"G2\/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex","volume":"89","author":"Berger","year":"2015","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e01433-16","DOI":"10.1128\/mBio.01433-16","article-title":"Activation of the DNA Damage Response Is a Conserved Function of HIV-1 and HIV-2 Vpr That Is Independent of SLX4 Recruitment","volume":"7","author":"Fregoso","year":"2016","journal-title":"Mbio"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/s41564-020-0753-6","article-title":"Vpu modulates DNA repair to suppress innate sensing and hyper-integration of HIV-1","volume":"5","author":"Volcic","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.chom.2017.12.009","article-title":"Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo","volume":"23","author":"Yamada","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1074\/jbc.M110.190538","article-title":"Structural and biophysical analysis of BST-2\/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release","volume":"286","author":"Swiecki","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1128\/JVI.00252-06","article-title":"Contribution of Vpu, Env, and Nef to CD4 Down-Modulation and Resistance of Human Immunodeficiency Virus Type 1-Infected T Cells to Superinfection","volume":"80","author":"Wildum","year":"2006","journal-title":"J. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Cisneros, W.J., Cornish, D., and Hultquist, J.F. (2022). Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation. Pathogens, 11.","DOI":"10.3390\/pathogens11080891"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"39823","DOI":"10.7554\/eLife.39823","article-title":"A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV","volume":"7","author":"OhAinle","year":"2018","journal-title":"Elife"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41587-022-01299-x","article-title":"CRISPR comes a-knock-in to reprogram antibodies in vivo","volume":"40","author":"Hartweger","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"649896","DOI":"10.3389\/fmed.2021.649896","article-title":"CRISPR\/Cas: Advances, Limitations, and Applications for Precision Cancer Research","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41592-018-0011-5","article-title":"CRISPR off-target analysis in genetically engineered rats and mice","volume":"15","author":"Anderson","year":"2018","journal-title":"Nat. Methods"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt.2916","article-title":"Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease","volume":"32","author":"Kuscu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","article-title":"Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity","volume":"63","author":"Tycko","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.celrep.2020.01.071","article-title":"CD32(+)CD4(+) T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency","volume":"30","author":"Darcis","year":"2020","journal-title":"Cell Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature21710","article-title":"CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses","volume":"543","author":"Descours","year":"2017","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR\/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A split-Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetsche","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery Aspects of CRISPR\/Cas for in Vivo Genome Editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dong, W., and Kantor, B. (2021). Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR\/Cas: Current State and Perspectives. Viruses, 13.","DOI":"10.3390\/v13071288"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","article-title":"Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease","volume":"21","author":"Uchida","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Gurumoorthy, N., Nordin, F., Tye, G.J., Zaman, W.S.W.K., and Ng, M.H. (2022). Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010107"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Shalaby, K., Aouida, M., and El-Agnaf, O. (2020). Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197353"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.1002\/ange.201506030","article-title":"Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing","volume":"127","author":"Sun","year":"2015","journal-title":"Angew. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1563\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:55Z","timestamp":1760119495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":140,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021563"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021563","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}